Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IgD-Fc-Ig
- Development stage
- Unknown
- Lead developer
- Anhui Medical University
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
IgD-Fc-Ig is a **recombinant fusion protein** composed of the Fc region of human Immunoglobulin D (IgD) linked to the Fc region of human IgG1. It acts as a selective blocker of the interaction between IgD and its receptor (IgDR, also called FcδR), thereby inhibiting the downstream signaling that drives abnormal T cell and B cell proliferation and activation. IgD-Fc-Ig was designed to reduce the pathological immune activation seen in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as certain malignancies like T-cell acute lymphoblastic leukemia. Preclinical and animal model data indicate it may restore immune balance by suppressing Th17 cell development and restoring Th17/Treg cell ratios. Its mechanism leverages prolonged half-life (from the IgG1-Fc domain) and reduced immunogenicity through selective targeting and blockade of the IgD/IgDR pathway[2][4][5][6].
- Brand names
- IgD-Fc-Ig
- Other names
- IgD-Fc-Ig fusion protein
Beyond the preview
Go deeper on IgD-Fc-Ig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IgD-Fc-Ig.